Intra-Cellular Therapies, Inc. Forecast, price target & analysts
Intra-Cellular Therapies, Inc. Target price 2025 - Analyst rating & recommendation
Intra-Cellular Therapies, Inc. Classifications & Recommendation:
Intra-Cellular Therapies, Inc. Price Target
| Target Price | $132.00 |
| Price | $128.25 |
| Potential |
2.92%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Intra-Cellular Therapies, Inc. 2026 .
The average Intra-Cellular Therapies, Inc. target price is $132.00.
This is
2.92%
register free of charge
$132.00
2.92%
register free of charge
$132.00
2.92%
register free of charge
|
|
| A rating was issued by 12 analysts: 2 Analysts recommend Intra-Cellular Therapies, Inc. to buy, 10 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Intra-Cellular Therapies, Inc. stock has an average upside potential 2026 of
2.92%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 680.85 | 929.89 |
| 46.62% | 36.58% | |
| EBITDA Margin | -17.07% | 8.10% |
| 50.10% | 147.46% | |
| Net Margin | -11.23% | 6.84% |
| 66.36% | 160.88% |
13 Analysts have issued a sales forecast Intra-Cellular Therapies, Inc. 2025 . The average Intra-Cellular Therapies, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Intra-Cellular Therapies, Inc. EBITDA forecast 2025. The average Intra-Cellular Therapies, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
13 Intra-Cellular Therapies, Inc. Analysts have issued a net profit forecast 2025. The average Intra-Cellular Therapies, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.72 | 0.60 |
| 50.68% | 183.33% | |
| P/E | 214.23 | |
| EV/Sales | 13.60 |
13 Analysts have issued a Intra-Cellular Therapies, Inc. forecast for earnings per share. The average Intra-Cellular Therapies, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Intra-Cellular Therapies, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Intra-Cellular Therapies, Inc....
Current Intra-Cellular Therapies, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Mizuho | Locked ➜ Locked | Locked | Feb 24 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 21 2025 |
| Canaccord Genuity | Locked ➜ Locked | Locked | Jan 31 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Jan 22 2025 |
| Piper Sandler | Locked ➜ Locked | Locked | Jan 14 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 13 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Nov 04 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Mizuho: Locked ➜ Locked
|
Feb 24 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 21 2025 |
|
Locked
Canaccord Genuity: Locked ➜ Locked
|
Jan 31 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Jan 22 2025 |
|
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 14 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 13 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Nov 04 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
